Why the FDA breakthrough pathway matters for Laguna Diagnostics’ psychiatric test
Psychiatry needs objective diagnostics. Laguna Diagnostics now faces the harder test: proving mRNA biomarkers can scale in real care.
What Alto Neuroscience’s ALTO-101 setback reveals about the difficulty of treating cognitive impairment in schizophrenia
Alto Neuroscience’s ALTO-101 missed in Phase 2. Read what the setback means for schizophrenia cognition, partnering prospects, and ALTO-207 next.
Can Alto Neuroscience’s ALTO-101 finally move the needle on cognitive impairment in schizophrenia?
Alto Neuroscience completes Phase 2 enrollment for ALTO-101 in CIAS. Discover what the upcoming data could mean for precision psychiatry.
HMNC Brain Health reports Phase 2b efficacy signals for BH-200 in genetically defined depression patients at ACNP
Find out how HMNC Brain Health’s Phase 2b BH-200 data at ACNP reveal genetic responder signals that could advance precision psychiatry in depression treatment.